Tag
This study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.
In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.
The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tum
